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Anticancer treatments aiming at killing malignant cells have been applied for decades but have been unsuccessful
at curing the disease. The modern concept of tumor microenvironment, especially angiogenesis, suggests that the
tumor is not only composed of malignant cells, but also consists of other groups of cells that work together.
Recently, genetic message transfer has been revealed between tumor cells and their microenvironment. The latest
cell-derived vector, extracellular membrane microvesicles (EMVs), has been found to provide membrane protection
and allowed to deliver genetic information beyond the cells. Additionally, EMV-associated microRNAs are involved
in a variety of cellular pathways for tumor initiation and progression. Previous published reviews have focused on
miRNA that included EMVs as a sensitive marker for tumor monitoring in clinical applications that are based on the
alteration of their expression levels in conjunction with disease occurrence and progression. From the aspect of
cellular crosstalk, this article will review the role of EMV-mediated microRNA transfer in tumor pathogenesis,
including tumor treatment obstacles, history and features, and current research in inflammatory/immune pathologies,
as well as in solid tumors and hematological malignancies. This nascent crosstalk model will provide a novel insight into
complementing the classic mechanisms of intercellular communication and contribute to the potential therapeutic
strategy via small RNA molecule-carrying EMVs for multimodality treatment of cancer.
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Cancer is a leading cause of death in developed nations
and a growing worldwide epidemic. Previous understand-
ing of tumor pathogenesis mainly focused on the tumor
itself, including the identification of oncogenes and sup-
pressor genes. Accordingly, current anticancer therapies
are mainly by means of surgery, radiation, and chemother-
apy, which directly target the malignant compartment.
However, cancer, the majority of which is still incurable,
has evolved to be one of the most remarkable global prob-
lems. There are unexpected obstacles which prevent con-
ventional treatments by using tumor-targeted toxins and
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depth. The latest perspectives in oncology have begun to
change from autonomous mechanisms of malignant cells
to crosstalks with other nonmalignant adjacent compo-
nents. A new concept, tumor microenvironment, is being
placed forward to explain the reciprocal causation between
tumors and their surrounding components, and this may
potentially overcome the existing therapeutic limitations.
Tumor microenvironment was firstly described by Judah
Folkman in 1971 [1] and has been recognized as one of
the major hallmarks of cancer. Referring to the National
Cancer Institute (NCI) Dictionary of Cancer Terms, a
tumor microenvironment represents a well-orchestrated
integration where the tumor exists and is constituted by
surrounding blood vessels, immune cells, fibroblasts, other
cells, signaling molecules, and the extracellular matrix.
This concept was based on the ‘seed and soil’ hypothesisThis is an Open Access article distributed under the terms of the Creative
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English surgeon Stephen Paget in 1889. Then, it was pre-
sented to describe tumor cell-host cell interactions for the
first time by the American scholar Lord EM, et al. in the
1970s [2]. These encouraging studies on tumor micro-
environment led to new perspectives for anticancer ther-
apy [3] and paved the way to the birth of thalidomide, the
first-generation immunomodulatory drug, into the antitu-
mor regimen in the early years of the past century. Since
then, many efforts have been made to design novel thera-
peutic drugs and conduct clinical trials, aiming to influ-
ence the ongoing pro-tumor environment.
The role of angiogenesis in the tumor microenviron-
ment has always retained an essential focus in preclinical
medical research on tumor progression. It was presented
by Willis in 1948 and originated from the hypothesis of
angiogenesis-dependent tumor, as tumor cells were ob-
served to acquire a new phenotype to participate in the
formation of blood channels [4]. Thereafter, it has in-
spired new investigations to clarify the mechanism of
angiogenesis. To date, pro-tumor angiogenesis has been
developed as a pivotal therapeutic target in the clinical
setting, especially for lymphoproliferative disease, such
as multiple myeloma (MM) and aggressive lymphoma.
Sprouting formation and splitting growth are two primary
ways of angiogenesis development in which both are
initiated from the preexisting vasculature. This is different
from angioblast-mediated vasculogenesis. Angiogenesis
and vasculogenesis potentially play distinct roles and may
be the center part in the etiology of primary and recurrent
neoplasms, respectively [5]. Although blockade in both an-
giogenic and vasculogenic pathways are attractive theoret-
ical targets, in clinic work, only the first and second
generation of anti-angiogenic therapies have been widely
used as one of the most rapidly developing aspects of anti-
cancer treatment, to some extent, because a series of ques-
tions concerning the role of vasculogenesis still remains
unanswered. Additionally, a mutated mouse model with
defective angiogenesis presented its resistance to trans-
planted tumors [6]. This suggested that angiogenesis may
be involved in tumor growth with more power than vascu-
logenesis. Hence, the studies of tumor angiogenesis have
continuously attracted more attention in tumorigenesis,
which waits for a better understanding of the interaction
between malignant cells and epithelial cells in the
microenvironment.
The discovery of the tumor microenvironment, angio-
genesis, raises an important question on the interplay
between cancer cells and their neighboring components;
how do cancer cells deliver messages to the remaining
normal endothelial capillaries? In addition to that, the
neovasculogenesis, the tumor microenvironment, mainly
harbors genetic arrangement abnormalities. Significantly,
the consensus tumor-specific genetic aberrations werefound in both tumor cells and the corresponding mi-
crovascular endothelial cells [7-9]. Two classic models of
cellular mutual communication, namely, the direct cell-to-
cell contact and the membrane receptors with ligands,
allow comprehending the possibility of tumor-induced
endothelial-cell growth in the microenvironment. How-
ever, taking into consideration the wide spread of extra-
cellular nucleases, responsible for the rapid clearance of
extracellular secretion of nucleic acid fragments, both
models are inappropriate methods to explain why the
neoplastic epithelium exhibits specific genetic abnor-
malities or whether any special carriers for transferring
nucleic acids into the cells already existed within the
tumor niche or just evolved from the distant regions.
This review will focus on discussing novel mechanisms
that trigger and influence the tumor and microenviron-
ment crosstalk.
Extracellular membrane microvesicles, mainly aggregating
and selectively including miRNAs, are uncovered as a
nascent crosstalk model for cellular communication
History and concept of EMVs
Extracellular membrane microvesicles (EMVs), new per-
formers participating in microenvironment conformation,
are circular fragments of membrane released from the
endosomal compartments as exosomes with diameters of
30 to 100 nm or shedding from the surface membranes of
most cell types as microvesicles with diameters of 50 to
2,000 nm [10]. Recently, EMVs are encouragingly observed
to carry and release deoxyribonucleic acid (DNA), message
ribose nucleic acid (mRNA), microRNAs (miRNAs), and
proteins to target locations or associated cells [11-13]. The
original concept of EMVs dates back to 1946 when
Chargaff and West hypothesized that cell-free plasma may
contain a subcellular factor promoting the clotting of
blood [14]. Twenty years later, microvesicles were ob-
served under the electron microscope which were derived
from platelets [15]. The other type of EMVs, exosomes,
was found by Johnstone et al. from sheep reticulocytes in
1987 [16]. These studies established a foundation for the
latest findings which discovered EMVs in bodily fluids
[17], namely, blood, urine, and bile [18-20], and more re-
cently in the tumor microenvironment. Until now, differ-
ential ultracentrifugation, the golden standard method for
separating and purifying EMVs, is incapable of distinguish-
ing between exosomes and microvesicles [21]. In contrast,
commercial kits are based on the principle of aqueous
gradient solubility differences between various lipids
and nanoparticles to capture EMVs and then use either
0.2-micrometer (μm) pore size filters or artificially syn-
thesized molecular sieves to enrich exosomes. In this
review, we describe EMVs that include both exosomes
and microvesicles because they cannot be precisely sep-
arated by current methods.
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As a novel class of regulators, miRNAs are the core ele-
ments in EMVs. Sequence analysis showed that there
was a diverse collection of the exosomal RNA species
among which miRNAs were the most abundant, making
up over 76% of all mappable reads [22]. miRNAs are en-
dogenous approximately 22 nt RNAs that play important
gene regulatory roles to specify mRNA cleavage or re-
pression of translation by pairing to the messages of
protein-coding genes [23]. In total, 2,588 mature human
miRNAs have been registered at the miRBase 21.0 and
are predicted to target more than 5,300 human genes,
which represented 30% of our exome [24], and the
miRNA-mRNA regulatory network reflects extremely sub-
tle combinatorics, both in terms of target multiplicity (more
than one target per miRNA) and signal integration (more
than one miRNA per target gene) [25]. Scientists have iden-
tified that vesicles which were released from both the hu-
man and murine mast cell lines contain approximately 121
miRNA molecules [26]. Moreover, miRNA expression has
been defined in circulating plasma microvesicles of normal
subjects [27]. Recent lines of evidence have revealed that
miRNA exchange between cells may be accomplished
through microvesicles [26]. In addition, other studies
showed that the specific miRNAs are primarily found ex-
tracellularly, and those may change depending on physio-
logical conditions [28,29]. It signifies that miRNA may be
transported to the extracellular compartment by being
selectively packed into the EMVs. Several studies have
proposed models to explain whether specific signaling
pathways exist to modify transport and packing of EMVs.
Studies have reported that the secretion of exosomes may
be triggered by the ceramide and neutral sphingomyeli-
nase, but not by the endosomal sorting complex as previ-
ously thought [30,31]. Specifically, purified exosomes were
observed to be enriched in ceramide and reduction of exo-
some release resulted from neutral sphingomyelinases in-
hibition [30,31]. We are just beginning to understand the
mechanisms of EMVs’ regulation, but the underlying mo-
lecular mechanisms involving microRNAs being in EMV
have yet to be elucidated. Occurrence of EMV-mediated
miRNA transfer has been indirectly confirmed by detect-
ing the altered expression levels of internal miRNAs in
both donor and recipient cells. In the future, fluorescence
signal amplification by a confocal imaging system may
allow us to directly study EMV transfer.
Characteristics of EMV-mediated miRNA transfer
The characteristics of EMV-mediated miRNA transfer
will be summarized in this section. (1) EMVs function as
the genetic messengers in intercellular communication
but differ from conventional cell-to-cell communication.
The circulating miRNAs have been found to be relatively
stable in the extracellular milieu and are resistant toplasma ribonucleases (RNase) with a long half-life, even
in the unfavorable physiological conditions such as
freeze-thawing and extreme pH and room temperature
[32-34]. These indicate that the EMV’s lipid bilayers
contribute to maintaining the stability of the circulating
miRNA to ensure the transfer of their genetic cargo to
the recipient cells. (2) As crosstalk mediators, EMVs
carry the miRNAs and exert the effects with high specifi-
city. Exosomes derived from the human T-lymphotropic
virus type 1-infected cells contain viral mRNA tran-
scripts [35], as well as tumor-derived MVs which were
elegantly demonstrated to have oncogene products into
the neighboring cells [36]. These miRNAs were select-
ively enriched into exosomes and selectively released de-
pending on not only the cell types of origin, namely, the
miRNA content differing among exosomes derived from
regulatory T cell (Treg) and T helper cell type 1 (Th1)
and T helper cell type 2 (Th2) cells [37], but also the cell
stage (mature dendritic cell (DC) cells versus immature
cells) [38], as well as the microenvironment context. The
content in exosome derived from DC cells in the cancer
microenvironment was found to differ from that in in-
fectious microenvironment [39]. (3) These natural small-
sized carriers have the ability to cross biological barriers
like the blood–brain barrier [40]. It is worthwhile to
note that they all originate from the host with no im-
munological rejection. This provides a great opportunity
to utilize them as potentially effective and safe vehicles
for transport genetic elements. (4) As membranous
structures, EMVs recycle continuously [41], indicating
that EMV-miRNAs are economic, efficient, and crucial
mediators in the human body. (5) EMVs, carrying their
genetic information, may be internalized by recipient
cells which may facilitate their cytoplasmic and nuclear
functions [42-44]. As shown in Figure 1, this specific
mode of transportation sets EMVs apart from traditional
modulators such as cytokines and their receptors.
EMV-mediated miRNA transfer in pathological conditions
The contribution of EMV-mediated miRNA transfer
on various pathological conditions has been addressed,
namely, trauma, inflammation, infection, and systematic
diseases. The transfer of genetic information from injured
cells, confirmed by the altered circulating levels of vascu-
lar and inflammation-associated miRNAs in inflammatory
patients [45], may explain how the functional and pheno-
typic changes in stem cells occur without the need of ex-
trinsic factors for transdifferentiation into tissue cells. This
evidence opens up the possibility to manipulate tissue re-
pair by the utilization of EMVs carrying specific miRNAs.
In addition to hemodynamic disorders like nephritic ische-
mia, hindlimb ischemia, and myocardial ischemia, EMVs,
derived from the mesenchymal cells, can protect organs
from acute ischemic injury by delivering their RNA
Figure 1 A new working model of EMV-mediated miRNA transfer in tumor. As crosstalk mediators, extracellular membrane microvesicles
(EMVs), which are derived from cancer cells, carry the selective microRNAs to exert the direct effects into (A) the homological cancer cells to
promote malignant transformation; (B) the neighboring cells, such as endothelial cells, to construct the tumor microenvironment; and (C)
peripheral circulation to be used as novel diagnostic biomarkers and prognostic monitoring. (D) Meanwhile, cancer cells can also be influenced
by absorbing miRNA-containing EMVs from the adjacent nonmalignant cells. MV, microvesicle; miRNA, microRNA.
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resident parenchymal cells to initiate the regenerative pro-
gram [46-49]. The studies of EMV-containing immune-
related miRNAs suggest that they may have the potential
to be a novel mechanism in modulating the immune sys-
tem [50]. Moreover, they may be a biomarker of auto-
immune diseases such as systemic lupus erythematosus
(SLE) [51]. Certain patterns of serum miRNAs are believed
to be mediated by the EMVs [52]. EMVs may help eluci-
date the possible pathogenesis of SLE [53].
Transfer of miRNAs by extracellular membrane
microvesicles in the context of tumor pathogenesis,
especially the microenvironment
EMV-mediated miRNA transfer in tumor pathogenesis
EMV-miRNA transfer plays a crucial role in tumor pa-
thogenesis and may be useful in clinical practice. These
aspects can be summarized as four key points. (1) Tumor-
derived EMVs can promote malignant transformation via
horizontal propagation of selective oncogenes. miRNAs
contribute to carcinogenesis not only as oncogenes, (miR-
9 detected in EMVs) [54,55], but also as the tumor sup-
pressor genes (miR-21 found in EMVs) [27,56]. (2) The
EMV-mediated miRNA transfer determines the fate of the
cells by controlling growth or death. Anti-apoptotic miR-
NAs, the miR-17 cluster, are detected in peripheral blood
microvesicles [27] while the serum levels of the homo-
logous series of these miRNAs are usually up regulated in
some cancers [57]. (3) EMV-mediated miRNA transfer
may drive invasion and metastasis of tumors. At least30 miRNAs have anti-angiogenic and pro-angiogenic
functions in cancers [58]. Yang et al. confirmed that
microvesicles shuttle invasion of miRNAs into cancer cells
[59]. Two groups of investigators demonstrated that
microvesicles modulated the establishment of metastasis
[60,61]. (4) EMVs may be used as novel diagnostic bio-
markers and in prognostic monitoring due to their stable
existence in ubiquitous biological fluids and miRNA panel
specific for cancer’s pathophysiological processes. Further-
more, EMVs may be used as potential vehicles to select-
ively deliver therapeutic nucleic-acid drugs or conventional
drugs for tumor therapy. As described in Table 1, in view
of this field, the plasma EMV-containing miRNA panel as
a sensitive and tumor-specific marker has become a hot
topic in the majority of solid tumors, to a large extent,
which represents the biological behavior of the tumor it-
self. However, research on hematological malignancies has
focused on the function of EMVs in the pathogenic cross-
talk between tumor cells and pericytes, which is expected
to make pivotal contributions to the construction of the
tumor microenvironment.
EMV-mediated miRNA transfer in solid tumor
EMVs are secreted by many cell types but cancer cells
have a higher production of them. Prostate cancer (PC)
is the first model which has been profoundly studied in
this area [62,63]. Lehmann et al. observed that the senes-
cence of radiation-induced PC cells was associated with
a significant increase in the release of EMVs containing
a large number of small RNAs (<100 base pairs (bp))
Table 1 List of EMV-mediated miRNA transfer in tumor pathogenesis as well as inflammatory/immune pathologies
Disease The given name of
EMVs
EMVs’ derivation EMVs’ target Involved
miRNAs
Research content References





Atherosclerosis MV THP-1 cells HMEC-1 miR-150 Enhancing migration [34]
Inflammation Exosome Tregs Th1 cells Let-7d Preventing inflammation [37]
Kidney ischemia-
reperfusion injury
MV EPCs Hypoxic resident
renal cells
miR-126 miR-296 Protecting resident kidney [46]
Hindlimb ischemia MV EPCs Endothelial cells miR-126 miR-296 Pro-neovascularization [48]
Breast cancer MV Macrophages Cancer cells miR-223 Promoting invasion [59]
Gastric cancer Exosome AZ-P7a cells Microenvironment Let-7 Pro-oncogenesis [89]
Leukemia Exosome K562 cells HUVECs miR-17-92 Enhancing migration and
tube formation
[90]
MM Exosome BMSC MM cells miR-15 Facilitating progression [92]
Glioblastoma
multiforme
MV Serum Circulating N/A Diagnostic marker [29]
PC Exosome PC-3 Conditioned media N/S Mediating intercellular
communication
[63]
Melanoma Exosome Serum Circulation miR-125b Monitor indicator [67]







Ovarian cancer Exosome Serum Circulation N/S Diagnostic marker [71]
Breast cancer Exosome Serum Circulation miR-21 Monitor indicator [73]
Lung cancer Exosome Serum Circulation N/S Diagnostic marker [74]
NSCLC Exosome Serum Circulation miR-21 miR-155 Diagnostic marker [75]
MC/9: Mouse mast cell line; HMC-1: Human mast cell line; THP-1: Human acute monocytic leukemia-1 cell line; HMEC-1: Human dermal microvascular endothelial
cell line; PC-3: Prostate cancer cell line; Hep3B, HepG2, PLC/PRF/5: Human HCC cell lines; AZ-P7a cells: Human metastatic duodenal cancer cell lines; K562: Human
chronic myeloid leukemia cell line; N/A: Not applicable; N/S: Not specified; MVs: Microvesicles; Treg: regulatory T cell; Th1: T helper cell type 1; EPCs: Endothelial
progenitor cells; PC: Prostate cancer; HCC: Hepatocellular carcinoma; HUVECs: Human umbilical vascular endothelial cells; MM: Multiple myeloma; BMSC: Bone
marrow stromal cell; NSCLC: Non-small-cell lung cancer; EMVs: extracellular membrane microvesicles.
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firmed EMVs ‘as biomarker treasure chests’ for PC diag-
nosis [64]. One year later, Bryant et al. found that
circulating miRNAs, embedded in EMVs, may represent
potentially useful biomarkers for the diagnosis, staging,
and prognostic prediction of PC [65].
Since the initial studies, serum EMVs were revealed and
may be potential biomarkers in other tumors (Table 1) in-
cluding glioblastoma [29,66], melanoma [67], liver cancer
[68,69], gastric cancer [70], ovarian cancer [71,72], breast
cancer [73], lung carcinoma [74,75], and Ewing’s sarcoma
[76]. However, the roles of EMV-mediated miRNA trans-
fer are still largely unknown and should be studied further
in solid tumors.
EMV-mediated miRNA transfer in hematological
malignancies
Etiologically, Yamada et al. confirmed that the bovine
leukemia virus proteins were released with milk EMVs
and may be transferred into recipient cells of calves via
milk EMVs as an alternative route without requiring avirus infection [77]. In chronic myelogenous leukemia,
BCR-ABL1-positive EMVs could initiate malignant trans-
formation of normal hematopoietic transplants through
genomic instability [78]. Circulating microvesicles during
chronic lymphoproliferative diseases were detected and
channels regulating leukemia-cell-derived EMV formation
were previously discussed [79,80]. Treatment by natural
killer cell suppression also involves EMVs [81,82]. Patients
who accepted stem cell therapeutic strategies may benefit
from the manipulation of paracrine EMVs [83]. Src was
shown to play a role in promoting angiogenesis in chronic
myeloid leukemia and enrichment of EMVs in malignant
plasma cell dyscrasia [84,85]. The effect of EMVs on mye-
loma has been discussed in the context of tumor cell pro-
liferation and angiogenesis [86-88].
EMV-mediated miRNA transfer in tumorous angiogenesis
Cancer cells can utilize EMV-mediated miRNA trans-
duction to constitute their microenvironments in stimu-
lating angiogenesis. Tumor EMVs, prostate, breast, and
ovarian cancers and some hematological neoplasms,
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malignant cells and may acquire tumor-supporting cha-
racteristics, namely, vasculogenic and epithelial markers.
Zhang et al. showed that human leukemia cell line THP-1
cells selectively packaged miR-150 into multivesicular
bodies and actively secreted them into the extracellular
environment to enhance target endothelial cell migration
[34]. Keiichi Ohshima et al. demonstrated that gastric can-
cer cells secreted let-7 miRNAs via exosomes into the
extracellular environment to maintain the process of
oncogenesis [89]. Szczepanski et al. reported that blast-
derived microvesicles in sera from patients with acute
myeloid leukemia suppress natural killer cell function by
membrane-associated transforming growth factor-beta1
[81]. Umezu et al. first circumstantiated that leukemia-
endothelial cell communication via exosomal miRNA
may, in part, be associated with angiogenic activity in
endothelial cells [90]. Recently, Tadokoro showed that
exosomes derived from hypoxic leukemia cells enhanced
tube formation in endothelial cells [91]. In animal models
and human samples, bone marrow mesenchymal stromal
cell (BM-MSC)-derived exosomes were reported to have
effects on viability, proliferation, survival, migration, and
drug resistance of MM cells [92,93]. Luga reported that
fibroblast-secreted exosomes promote breast cancer cell
protrusive activity and motility by Wnt-planar cell polarity
signaling [94]. Moreover, tumor-microenvironment-cell-
derived-EMVs may act on other cells types. In 1998, stud-
ies on exosomes derived from antigen present cells (APCs)
demonstrated that they have the capacity to prime naive
CD8+ T lymphocytes to eradicate tumors [95]. Gastpar
showed for the first time that exosomes originating from
Hsp70/Bag-4 membrane-positive tumor cells stimulated
the migration and reactivity of Hsp70 in natural killer
(NK) cells [96]. Cell communication via EMVs is compli-
cated but fascinating and participates not only in normal
physiology but also in pathological phenomena, namely,
cancer. Research studies have found a variety of func-
tions of EMVs and further attention needs to be fo-
cused in this area.
Summary
EMVs are novel and unique effectors carrying out many
biological messages. Aside from their conventional basal
intracellular communications, EMVs can also actively
participate in triggering signal pathways and exclusively
transfer nucleic acids as miRNA clusters. Due to its char-
acteristics, microvesicle-mediated miRNA transduction is
one of the first autogenous mediators to exchange specific
and endogenous tumor-related genetic signals among
multiple types of cells, which has attracted more attention
on malignant cell-endothelial cell interaction in the
tumor microenvironment. Therapy by microvesicle-
mediated miRNA transduction may aid in drug resistanceand inhibition of tumor invasion. Collectively, these
studies suggest that this novel intracellular model com-
plements the classic cell-to-cell communication and
provides new therapeutic strategies for both solid can-
cers and hematological disorders.
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